Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Stanolone
- Accession Number
- DB02901 (EXPT01199)
- Type
- Small Molecule
- Groups
- Illicit, Investigational
- Description
A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.
- Structure
Structure for DB02901 (Stanolone)
- Synonyms
- 17beta-Hydroxy-5alpha-androstan-3-one
- 17beta-Hydroxy-5alpha-androstane-3-one
- 17beta-Hydroxyandrostan-3-one
- 17β-hydroxy-3-oxo-5α-androstanone
- 17β-hydroxy-5α-androstan-3-one
- 4-Dihydrotestosterone
- 5alpha-Dihydrotestosterone
- 5α-DHT
- Androstanolone
- DHT
- Dihydrotestosteron
- Dihydrotestostérone
- Dihydrotestosterone
- International/Other Brands
- Anaboleen / Anabolex / Anaprotin / Andractim / Androlone / Cristerona MB / Neodrol / Proteina / Protona / Stanaprol
- Categories
- 5-Androstanon (3) Derivatives
- Alimentary Tract and Metabolism
- Anabolic Agents for Systemic Use
- Anabolic Steroids
- Androgens
- Androstan Derivatives
- Androstanes
- Androstanols
- Genito Urinary System and Sex Hormones
- Gonadal Hormones
- Gonadal Steroid Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- P-glycoprotein/ABCB1 Substrates
- Sex Hormones and Modulators of the Genital System
- Steroids
- Testosterone Congeners
- UNII
- 08J2K08A3Y
- CAS number
- 521-18-6
- Weight
- Average: 290.4403
Monoisotopic: 290.224580204 - Chemical Formula
- C19H30O2
- InChI Key
- NVKAWKQGWWIWPM-ABEVXSGRSA-N
- InChI
- InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
- IUPAC Name
- (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one
- SMILES
- [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UEstradiol 17-beta-dehydrogenase 1 Not Available Human UAndrogen receptor Not Available Human UEstrogen receptor alpha Not Available Human UMineralocorticoid receptor Not Available Human - Absorption
Bioavailability is very low (0-2%) following oral administration.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Oral LD50 in rat is 7060 mg/kg. Oral LD50 in mouse is 3450 mg/kg.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone 16-Bromoepiandrosterone may increase the fluid retaining activities of Stanolone. Investigational 19-norandrostenedione 19-norandrostenedione may increase the fluid retaining activities of Stanolone. Experimental, Illicit 5-androstenedione 5-androstenedione may increase the fluid retaining activities of Stanolone. Experimental, Illicit Acarbose Stanolone may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acenocoumarol Stanolone may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Albiglutide Stanolone may increase the hypoglycemic activities of Albiglutide. Approved Alclometasone Alclometasone may increase the fluid retaining activities of Stanolone. Approved Aldosterone Aldosterone may increase the fluid retaining activities of Stanolone. Experimental, Investigational Alogliptin Stanolone may increase the hypoglycemic activities of Alogliptin. Approved Amcinonide Amcinonide may increase the fluid retaining activities of Stanolone. Approved Amlodipine The serum concentration of Stanolone can be increased when it is combined with Amlodipine. Approved Androstenedione Androstenedione may increase the fluid retaining activities of Stanolone. Experimental, Illicit Anecortave Anecortave may increase the fluid retaining activities of Stanolone. Investigational anecortave acetate anecortave acetate may increase the fluid retaining activities of Stanolone. Investigational Apalutamide The serum concentration of Stanolone can be decreased when it is combined with Apalutamide. Approved, Investigational Atamestane Atamestane may increase the fluid retaining activities of Stanolone. Investigational Beclomethasone dipropionate Beclomethasone dipropionate may increase the fluid retaining activities of Stanolone. Approved, Investigational Betamethasone Betamethasone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Bromocriptine Stanolone may increase the hypoglycemic activities of Bromocriptine. Approved, Investigational Budesonide Budesonide may increase the fluid retaining activities of Stanolone. Approved Canagliflozin Stanolone may increase the hypoglycemic activities of Canagliflozin. Approved Chlorpropamide Stanolone may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Ciclesonide Ciclesonide may increase the fluid retaining activities of Stanolone. Approved, Investigational Clobetasol Clobetasol may increase the fluid retaining activities of Stanolone. Approved, Investigational Clobetasol propionate Clobetasol propionate may increase the fluid retaining activities of Stanolone. Approved Clobetasone Clobetasone may increase the fluid retaining activities of Stanolone. Approved Clocortolone Clocortolone may increase the fluid retaining activities of Stanolone. Approved Clorindione Stanolone may increase the anticoagulant activities of Clorindione. Experimental Conestat alfa Stanolone may increase the thrombogenic activities of Conestat alfa. Approved, Investigational Cortexolone 17α-propionate Cortexolone 17α-propionate may increase the fluid retaining activities of Stanolone. Investigational Corticosterone Corticosterone may increase the fluid retaining activities of Stanolone. Experimental Cortisone acetate Cortisone acetate may increase the fluid retaining activities of Stanolone. Approved, Investigational Cyclosporine Stanolone may increase the hepatotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dapagliflozin Stanolone may increase the hypoglycemic activities of Dapagliflozin. Approved Deflazacort Deflazacort may increase the fluid retaining activities of Stanolone. Approved, Investigational Desonide Desonide may increase the fluid retaining activities of Stanolone. Approved, Investigational Desoximetasone Desoximetasone may increase the fluid retaining activities of Stanolone. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may increase the fluid retaining activities of Stanolone. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may increase the fluid retaining activities of Stanolone. Experimental, Vet Approved Dexamethasone Dexamethasone may increase the fluid retaining activities of Stanolone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may increase the fluid retaining activities of Stanolone. Vet Approved Dicoumarol Stanolone may increase the anticoagulant activities of Dicoumarol. Approved Diflorasone Diflorasone may increase the fluid retaining activities of Stanolone. Approved Difluocortolone Difluocortolone may increase the fluid retaining activities of Stanolone. Approved, Investigational, Withdrawn Difluprednate Difluprednate may increase the fluid retaining activities of Stanolone. Approved Diphenadione Stanolone may increase the anticoagulant activities of Diphenadione. Experimental Disopyramide Stanolone may increase the hypoglycemic activities of Disopyramide. Approved Dulaglutide Stanolone may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Empagliflozin Stanolone may increase the hypoglycemic activities of Empagliflozin. Approved Equilenin Equilenin may increase the fluid retaining activities of Stanolone. Experimental Equilin Equilin may increase the fluid retaining activities of Stanolone. Approved Estrone Estrone may increase the fluid retaining activities of Stanolone. Approved Estrone sulfate Estrone sulfate may increase the fluid retaining activities of Stanolone. Approved Ethyl biscoumacetate Stanolone may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Exenatide Stanolone may increase the hypoglycemic activities of Exenatide. Approved, Investigational Fluasterone Fluasterone may increase the fluid retaining activities of Stanolone. Investigational Fludrocortisone Fludrocortisone may increase the fluid retaining activities of Stanolone. Approved, Investigational Fluindione Stanolone may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone Flumethasone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Flunisolide Flunisolide may increase the fluid retaining activities of Stanolone. Approved, Investigational Fluocinolone Acetonide Fluocinolone Acetonide may increase the fluid retaining activities of Stanolone. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may increase the fluid retaining activities of Stanolone. Approved, Investigational Fluocortolone Fluocortolone may increase the fluid retaining activities of Stanolone. Approved, Withdrawn Fluorometholone Fluorometholone may increase the fluid retaining activities of Stanolone. Approved, Investigational Fluprednidene Fluprednidene may increase the fluid retaining activities of Stanolone. Approved, Withdrawn Fluprednisolone Fluprednisolone may increase the fluid retaining activities of Stanolone. Approved Flurandrenolide Flurandrenolide may increase the fluid retaining activities of Stanolone. Approved Fluticasone Fluticasone may increase the fluid retaining activities of Stanolone. Approved, Experimental, Investigational Fluticasone furoate Fluticasone furoate may increase the fluid retaining activities of Stanolone. Approved Fluticasone propionate Fluticasone propionate may increase the fluid retaining activities of Stanolone. Approved Formestane Formestane may increase the fluid retaining activities of Stanolone. Approved, Investigational, Withdrawn Gabexate Stanolone may increase the thrombogenic activities of Gabexate. Investigational Gliclazide Stanolone may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Stanolone may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Stanolone may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Stanolone may increase the hypoglycemic activities of Glyburide. Approved Halcinonide Halcinonide may increase the fluid retaining activities of Stanolone. Approved, Investigational, Withdrawn HE3286 HE3286 may increase the fluid retaining activities of Stanolone. Investigational Human C1-esterase inhibitor Stanolone may increase the thrombogenic activities of Human C1-esterase inhibitor. Approved Hydrocortisone Hydrocortisone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Insulin Aspart Stanolone may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Stanolone may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Stanolone may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Stanolone may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Stanolone may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Stanolone may increase the hypoglycemic activities of Insulin Lispro. Approved Isavuconazole The serum concentration of Stanolone can be increased when it is combined with Isavuconazole. Approved, Investigational Istaroxime Istaroxime may increase the fluid retaining activities of Stanolone. Investigational Liraglutide Stanolone may increase the hypoglycemic activities of Liraglutide. Approved Loteprednol Loteprednol may increase the fluid retaining activities of Stanolone. Approved Lumacaftor The serum concentration of Stanolone can be decreased when it is combined with Lumacaftor. Approved ME-609 ME-609 may increase the fluid retaining activities of Stanolone. Investigational Mecasermin Stanolone may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Medrysone Medrysone may increase the fluid retaining activities of Stanolone. Approved Melengestrol Melengestrol may increase the fluid retaining activities of Stanolone. Vet Approved Metformin Stanolone may increase the hypoglycemic activities of Metformin. Approved Methylprednisolone Methylprednisolone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Mifepristone Stanolone may increase the hypoglycemic activities of Mifepristone. Approved, Investigational Miglitol Stanolone may increase the hypoglycemic activities of Miglitol. Approved Mometasone Mometasone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Nateglinide Stanolone may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 NCX 1022 may increase the fluid retaining activities of Stanolone. Investigational Oleoyl-estrone Oleoyl-estrone may increase the fluid retaining activities of Stanolone. Investigational Paramethasone Paramethasone may increase the fluid retaining activities of Stanolone. Approved Pentamidine Stanolone may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Phenindione Stanolone may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Stanolone may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Pioglitazone Stanolone may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pitolisant The serum concentration of Stanolone can be decreased when it is combined with Pitolisant. Approved, Investigational Pramlintide Stanolone may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Prasterone Prasterone may increase the fluid retaining activities of Stanolone. Approved, Investigational, Nutraceutical Prasterone sulfate Prasterone sulfate may increase the fluid retaining activities of Stanolone. Investigational Prednicarbate Prednicarbate may increase the fluid retaining activities of Stanolone. Approved, Investigational Prednisolone Prednisolone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Prednisone Prednisone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Pregnenolone Pregnenolone may increase the fluid retaining activities of Stanolone. Approved, Experimental, Investigational Quinine Stanolone may increase the hypoglycemic activities of Quinine. Approved Ranolazine The serum concentration of Stanolone can be increased when it is combined with Ranolazine. Approved, Investigational Repaglinide Stanolone may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rimexolone Rimexolone may increase the fluid retaining activities of Stanolone. Approved Rosiglitazone Stanolone may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Saxagliptin Stanolone may increase the hypoglycemic activities of Saxagliptin. Approved Sitagliptin Stanolone may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sulfadiazine Stanolone may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Stanolone may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfisoxazole Stanolone may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sunitinib Stanolone may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Tioclomarol Stanolone may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol Tixocortol may increase the fluid retaining activities of Stanolone. Approved, Withdrawn Tolazamide Stanolone may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Stanolone may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Triamcinolone Triamcinolone may increase the fluid retaining activities of Stanolone. Approved, Vet Approved Ulobetasol Ulobetasol may increase the fluid retaining activities of Stanolone. Approved Vemurafenib The serum concentration of Stanolone can be increased when it is combined with Vemurafenib. Approved Warfarin Stanolone may increase the anticoagulant activities of Warfarin. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
A. Glenn Braswell, Aftab J. Ahmed, "Composition for inhibiting production of dihydrotestosterone to treat benign prostate hyperplasia." U.S. Patent US6264996, issued October, 1996.
US6264996- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002961
- KEGG Drug
- D07456
- KEGG Compound
- C03917
- PubChem Compound
- 10635
- PubChem Substance
- 46506828
- ChemSpider
- 10189
- BindingDB
- 18161
- ChEBI
- 16330
- ChEMBL
- CHEMBL27769
- HET
- DHT
- Wikipedia
- Dihydrotestosterone
- ATC Codes
- A14AA01 — Androstanolone
- A14AA — Androstan derivatives
- A14A — ANABOLIC STEROIDS
- A14 — ANABOLIC AGENTS FOR SYSTEMIC USE
- A — ALIMENTARY TRACT AND METABOLISM
- PDB Entries
- 1d2s / 1dht / 1f5f / 1i37 / 1i38 / 1kdk / 1kdm / 1t5z / 1t63 / 1t65 … show 34 more
- MSDS
- Download (111 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 181 °C PhysProp water solubility 525 mg/mL (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 3.55 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.00998 mg/mL ALOGPS logP 3.37 ALOGPS logP 3.41 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 19.38 ChemAxon pKa (Strongest Basic) -0.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 83.6 m3·mol-1 ChemAxon Polarizability 34.69 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9818 Caco-2 permeable + 0.8846 P-glycoprotein substrate Substrate 0.57 P-glycoprotein inhibitor I Non-inhibitor 0.5631 P-glycoprotein inhibitor II Non-inhibitor 0.846 Renal organic cation transporter Non-inhibitor 0.7884 CYP450 2C9 substrate Non-substrate 0.7715 CYP450 2D6 substrate Non-substrate 0.93 CYP450 3A4 substrate Substrate 0.7314 CYP450 1A2 substrate Non-inhibitor 0.6853 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.971 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8546 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9647 Ames test Non AMES toxic 0.9414 Carcinogenicity Non-carcinogens 0.9182 Biodegradation Not ready biodegradable 0.9686 Rat acute toxicity 1.9757 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9444 hERG inhibition (predictor II) Non-inhibitor 0.576
Spectra
- Mass Spec (NIST)
- Download (11.2 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-015c-8970000000-ef0c6a4fd9c52be30284 GC-MS Spectrum - EI-B GC-MS splash10-001l-1790000000-60cff73adc796876d469 Mass Spectrum (Electron Ionization) MS splash10-000x-9870000000-f6d80b2a53942c9af50b Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available 13C NMR Spectrum 1D NMR Not Applicable
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- 3-oxo-5-alpha-steroids / 17-hydroxysteroids / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- Androgen-skeleton / 3-oxosteroid / 3-oxo-5-alpha-steroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Cyclic alcohol / Cyclic ketone / Secondary alcohol / Ketone
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3-oxo steroid, 17beta-hydroxy steroid, 17beta-hydroxyandrostan-3-one (CHEBI:16330) / C19 steroids (androgens) and derivatives, Androstane and derivatives, Androgens (C03917) / C19 steroids (androgens) and derivatives (LMST02020042)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Testosterone dehydrogenase (nad+) activity
- Specific Function
- Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
- Gene Name
- HSD17B1
- Uniprot ID
- P14061
- Uniprot Name
- Estradiol 17-beta-dehydrogenase 1
- Molecular Weight
- 34949.715 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM: Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem. 2007 Aug 31;282(35):25801-16. Epub 2007 Jun 25. [PubMed:17591767]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Kojima H, Iida M, Katsura E, Kanetoshi A, Hori Y, Kobayashi K: Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities. Environ Health Perspect. 2003 Apr;111(4):497-502. [PubMed:12676605]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
- Gene Name
- NR3C2
- Uniprot ID
- P08235
- Uniprot Name
- Mineralocorticoid receptor
- Molecular Weight
- 107066.575 Da
References
- Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A: The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor. Mol Pharmacol. 2007 Feb;71(2):473-82. Epub 2006 Nov 14. [PubMed:17105867]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
- Specific Function
- Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
- Gene Name
- CYP11A1
- Uniprot ID
- P05108
- Uniprot Name
- Cholesterol side-chain cleavage enzyme, mitochondrial
- Molecular Weight
- 60101.87 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid 17-alpha-monooxygenase activity
- Specific Function
- Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
- Gene Name
- CYP17A1
- Uniprot ID
- P05093
- Uniprot Name
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Molecular Weight
- 57369.995 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
- Gene Name
- CYP19A1
- Uniprot ID
- P11511
- Uniprot Name
- Aromatase
- Molecular Weight
- 57882.48 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Androgen binding
- Specific Function
- Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
- Gene Name
- SHBG
- Uniprot ID
- P04278
- Uniprot Name
- Sex hormone-binding globulin
- Molecular Weight
- 43778.755 Da
References
- Metzger J, Schnitzbauer A, Meyer M, Soder M, Cuilleron CY, Hauptmann H, Huber E, Luppa PB: Binding analysis of 1alpha- and 17alpha-dihydrotestosterone derivatives to homodimeric sex hormone-binding globulin. Biochemistry. 2003 Nov 25;42(46):13735-45. [PubMed:14622020]
- Hauptmann H, Metzger J, Schnitzbauer A, Cuilleron CY, Mappus E, Luppa PB: Syntheses and ligand-binding studies of 1 alpha- and 17 alpha-aminoalkyl dihydrotestosterone derivatives to human sex hormone-binding globulin. Steroids. 2003 Sep;68(7-8):629-39. [PubMed:12957668]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC: P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90. [PubMed:14991868]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:58